Recent News

‘Breaking the mold with RNA—a “RNAissance” of life science’ – npj Genomic Medicine

Apr 2024

Beacon maps over 2300 lung cancer biomarkers in new global database – PBI Forum

Feb 2024

New day for antibody-drug conjugates – Chemical & Engineering News

May 2022

What makes a good antibody–drug conjugate? – Martin De Cecco, Daniel N. Galbraith & Lisa L. McDermottt

Feb 2021

Beacon Targeted Therapies announces the launch of Beacon Oncolytic Viruses

Jul 2020

Cell Therapy 2.0

Jul 2020

Overcoming Challenges in the Development of Anticancer ADCs

Jun 2020

Immuno-oncology cell therapies: commercial considerations and strategies for the new decade

Jun 2020

Beacon Targeted Therapies announces the launch of Beacon Gene Therapy

May 2020

Frontiers in Oncology – Perspective: Designing T-Cell Engagers With Better Therapeutic Windows

Apr 2020

Hot Topics at CAR-TCR 2020

Apr 2020

Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials

Feb 2020

TCR Therapies Summit 2020 Magazine

Feb 2020

Drug developers take fresh aim at ‘guided-missile’ cancer drugs

Jan 2020

CAR-TCR Europe Summit 2020 Magazine

Jan 2020

World ADC London 2020 Magazine

Jan 2020

Innate Killer Summit 2020 Magazine

Jan 2020

From Mylotarg to Polivy: Ebbs and flows, successes and woes of ADCs

Nov 2019

Trends & Forecasts – Tenacious ADCs

Nov 2019

World ADC San Diego Magazine 2019

Sep 2019

Biomarkers for Checkpoint Inhibition and Their Clinical Utility – Timothy James Fabisiak, B.A.

Jul 2019

Bispecific antibodies: a mechanistic review of the pipeline Aran F. Labrijn, Maarten L. Janmaat, Janice M. Reichert & Paul W. H. I. Parren

Jun 2019

Beacon Targeted Therapies Launches Beacon Adoptive Cell

May 2019

The Evolving Shape of the ADC Market: The Widening Application of ADCs and Manufacturing Improvements Meeting Demand – Charlie Johnson, CEO of ADC Bio,

Mar 2019

Antibodies to watch in 2019 – Hélène Kaplon & Janice M. Reichert

Dec 2018